• About us
• Contact

Advertisement

Organisation › Details

AstraZeneca plc (LSE: AZN)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. *

 

	Start	1999-04-05 merged
	Group	AstraZeneca (Group)
	Predecessor	Zeneca Group Plc
	Industry	pharmaceutical
	Person	Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)
	Person 2	Dunoyer, Marc (AstraZeneca 201311– CFO joined 201303 as EVP Global Portfolio + Product Strategy before GSK)
	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	1 Francis Crick Avenue Cambridge Biomedical Campus
	City	CB2 0AA Cambridge, Cambridgeshire
		Address record changed: 2024-01-05
Basic data	Employees	I: 50,001 to 100,0 (2022-12-31)
	Currency	USD
	Annual sales	44,351,000,000 (revenue, total, consolidated (2022) 2022-12-31)
	Profit	3,293,000,000 (2022-12-31)
	Cash	6,166,000,000 (2022-12-31)
		* Document for »About Section«: AstraZeneca plc. (11/29/22). "Press Release: AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy".
		Record changed: 2024-11-04

Advertisement

More documents for AstraZeneca (Group)

• [1] FibroGen, Inc.. (2/20/25). "Press Release: FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million". San Francisco, CA....
• [2] Qiagen N.V.. (8/28/24). "Press Release: Qiagen Expands QIAstat-Dx into Precision Medicine through Partnership for Companion Diagnostics in Chronic Diseases". Venlo....
• [3] Pinetree Therapeutics, Inc.. (7/23/24). "Press Release: Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca". Cambridge, MA....
• [4] Huma Therapeutics Ltd.. (7/16/24). "Press Release: Huma Completes Series D with Total Financing of over $80m as It Launches Huma Cloud Platform with GenAI Integrations to Bring Digital First Care and Research to Everyone". London & New York, NY....
• [5] AstraZeneca plc. (3/19/24). "Press Release: AstraZeneca to Acquire Fusion to Accelerate the Development of Next-generation Radioconjugates to Treat Cancer"....
• [6] Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA....
• [7] Allorion Therapeutics Inc.. (1/2/24). "Press Release: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca". Natick, MA....
• [8] Gracell Biotechnologies Inc.. (12/26/23). "Press Release: Gracell Biotechnologies to Be Acquired by AstraZeneca, furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases". San Diego, CA, Suzhou & Shanghai....
• [9] AstraZeneca plc. (12/26/23). "Press Release: AstraZeneca to Acquire Gracell, Furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases"....
• [10] AstraZeneca plc. (12/12/23). "Press Release: AstraZeneca to Acquire Icosavax, Including Potential First-in-Class RSV and hMPV Combination Vaccine with Positive Phase II Data"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.